Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- Buprenorphine: an overview for clinicians1
- Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder: final evidence report and meeting summary1
- Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report1
- Flexibilities in controlled substances prescribing and dispensing during the COVID-19 pandemic1
- Geographic disparities affect access to buprenorphine services for opioid use disorder1
- How community health centers are addressing the opioid epidemic: case study1
- Increasing access to medications for opioid use disorder: policy strategies during and after COVID-19 pandemic1
- Learning from COVID-19: how pandemic-era policies for methadone prescribing could improve opioid treatment1
- Lowering the barriers to medication treatment for people with opioid use disorder: evidence for a low-threshold approach1
- MAT for hospitalized patients1
- MAT for opioid use disorder: overcoming objections1
- MAT in the emergency department: FAQ1
- Many Medicaid enrollees with opioid use disorder were treated with medication: however, disparities present concerns1
- Opioid use decreased in Medicare Part D, while medication-assisted treatment increased1
- Opioid use disorder: barriers to Medicaid beneficiaries' access to treatment medications : report to Congressional committees1
- Opioid use disorder: treatment with injectable and implantable buprenorphine : report to Congressional committees1
- Opioid use disorders: HHS needs measures to assess the effectiveness of efforts to expand access to medication-assisted treatment : report to majority leader, U.S. Senate1
- Substitutes for opium in chronic diseases1
- Substitution: Damit hab ich HIV1
- Substitution: Meine Chance für Ausbildung und Beruf1